ATE287719T1 - Inhalierung von antiendotoxinmitteln zur vorbeugung oder behandlung von bakterieller lungeninfektion oder symptomatischer endotoxinaussetzung der lunge - Google Patents

Inhalierung von antiendotoxinmitteln zur vorbeugung oder behandlung von bakterieller lungeninfektion oder symptomatischer endotoxinaussetzung der lunge

Info

Publication number
ATE287719T1
ATE287719T1 AT00980723T AT00980723T ATE287719T1 AT E287719 T1 ATE287719 T1 AT E287719T1 AT 00980723 T AT00980723 T AT 00980723T AT 00980723 T AT00980723 T AT 00980723T AT E287719 T1 ATE287719 T1 AT E287719T1
Authority
AT
Austria
Prior art keywords
endotoxin
inhalation
lung
antiendotoxin
agents
Prior art date
Application number
AT00980723T
Other languages
English (en)
Inventor
Daniel P Rossignol
Mary W Vermeulen
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE287719T1 publication Critical patent/ATE287719T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00980723T 1999-11-23 2000-11-22 Inhalierung von antiendotoxinmitteln zur vorbeugung oder behandlung von bakterieller lungeninfektion oder symptomatischer endotoxinaussetzung der lunge ATE287719T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/449,601 US6417172B1 (en) 1995-06-05 1999-11-23 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
PCT/US2000/032177 WO2001037843A1 (en) 1999-11-23 2000-11-22 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs

Publications (1)

Publication Number Publication Date
ATE287719T1 true ATE287719T1 (de) 2005-02-15

Family

ID=23784778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980723T ATE287719T1 (de) 1999-11-23 2000-11-22 Inhalierung von antiendotoxinmitteln zur vorbeugung oder behandlung von bakterieller lungeninfektion oder symptomatischer endotoxinaussetzung der lunge

Country Status (9)

Country Link
US (2) US6417172B1 (de)
EP (1) EP1248629B1 (de)
JP (1) JP2003514862A (de)
AT (1) ATE287719T1 (de)
AU (1) AU1794601A (de)
CA (1) CA2392356A1 (de)
DE (1) DE60017801T2 (de)
ES (1) ES2237475T3 (de)
WO (1) WO2001037843A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6906042B2 (en) 2000-02-18 2005-06-14 Eisai Co., Ltd. Micelles
US20030105033A1 (en) 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
AU2001275520A1 (en) * 2000-06-09 2001-12-17 Eisai Co. Ltd. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
EP2338497A1 (de) * 2001-08-10 2011-06-29 Eisai R&D Management Co., Ltd. Behandlung und Vorbeugung von Hitzeschockprotein assoziierten Krankheiten und Leiden
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
SI1589934T1 (sl) * 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
WO2004074303A2 (en) * 2003-02-20 2004-09-02 Eisai Co, Ltd. Reagents and methods for preparing lps antagonist b1287 and stereoisomers thereof
WO2007026675A1 (ja) * 2005-08-31 2007-03-08 Eisai R & D Management Co., Ltd. リピッドａ類縁体の製造方法
EP2468300B1 (de) 2006-09-26 2017-12-20 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen Adjuvans
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2012047656A1 (en) * 2010-09-27 2012-04-12 The University Of British Columbia Lipid a analog compositions
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN113527396B (zh) * 2020-04-17 2024-02-02 上海医药工业研究院 一种疫苗佐剂mpla的中间体、合成及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations

Also Published As

Publication number Publication date
EP1248629B1 (de) 2005-01-26
JP2003514862A (ja) 2003-04-22
HK1051490A1 (en) 2003-08-08
EP1248629A4 (de) 2003-05-21
DE60017801T2 (de) 2006-01-05
CA2392356A1 (en) 2001-05-31
AU1794601A (en) 2001-06-04
WO2001037843A1 (en) 2001-05-31
US20030134805A1 (en) 2003-07-17
EP1248629A1 (de) 2002-10-16
US6417172B1 (en) 2002-07-09
ES2237475T3 (es) 2005-08-01
DE60017801D1 (de) 2005-03-03
US6683063B2 (en) 2004-01-27

Similar Documents

Publication Publication Date Title
DE60017801D1 (de) Inhalierung von antiendotoxinmitteln zur vorbeugung oder behandlung von bakterieller lungeninfektion oder symptomatischer endotoxinaussetzung der lunge
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
DE69916686D1 (de) Gerät zur Behandlung von Atemstillstand im Schlaf
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
SE0000601D0 (sv) Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
BR9916432A (pt) Compostos de triazinona para o tratamento de doenças devido ao sarcosystis, neospora e ao toxoplasma
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE448788T1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
ATE244008T1 (de) Verwendung von makroliden zur behandlung von akuten lungenverletzungen
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE239467T1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE69924979D1 (de) Behandlung von chronischen schmerzen
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
ATE308895T1 (de) Behandlung von infektionen in tieren
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties